Artelo Biosciences Secures Another Highly Dilutive Convertible Note Amidst Financial Distress
ARTL is trading near its 52-week low of $2.955 (12% above the low).
Summary
Artelo Biosciences obtained $300,000 in highly dilutive convertible note financing with punitive terms, while also announcing a strategic expansion for its ART27.13 drug candidate in muscle preservation.
Key Events · Financing and Capital Events · ARTL
-
Secured Highly Dilutive Convertible Note
The company entered into a Securities Purchase Agreement for a 10% promissory note with a principal amount of $315,000, issued for a purchase price of $300,000. This financing includes an original issue discount of $15,000.
-
Aggressive Conversion and Default Terms
The note is convertible into common stock at 75% of the average of the two lowest closing bid prices during the 10 trading days prior to conversion. Upon an Event of Default, the company must pay 150% of the outstanding principal plus accrued interest. The investor also has a 'Most Favored Nation' clause and a 'Dilutive Issuance' clause, allowing for conversion price adjustments if more favorable terms are offered to other investors.
-
Investor Control Over Future Proceeds
The investor has the right to demand repayment of up to 25% of any future cash proceeds received by the company from any source, including equity or debt issuances, as long as the note is outstanding.
-
Strategic Drug Development Expansion for ART27.13
The company announced a strategic expansion opportunity for its ART27.13 drug candidate in muscle preservation for patients undergoing GLP-1 receptor agonist therapy, supported by preclinical observations, independent research, a provisional patent filing, and a new non-clinical study.
Analysis · ARTL · Life Sciences
Artelo Biosciences has secured an additional $300,000 in bridge financing through a highly dilutive convertible promissory note, adding to a series of capital raises in recent weeks. The note, with a principal amount of $315,000 and 10% interest, allows the investor to convert into common stock at a significant discount (75% of the average of the two lowest closing bid prices over 10 days). This structure, coupled with a 150% default penalty and aggressive anti-dilution provisions, indicates the company's urgent need for capital given its previously disclosed 'going concern' warning. While the company also announced positive early-stage developments for its ART27.13 drug candidate in muscle preservation for GLP-1 therapy, the immediate and severe dilutive nature of this financing, along with the investor's strong control rights over future cash flows, presents a critical negative signal for existing shareholders. The positive drug news, though potentially significant long-term, is overshadowed by the company's immediate financial challenges and the unfavorable terms of this capital infusion.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTL was trading at $3.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $2.96 to $85.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.